ICLE 2022 | Evaluating the therapeutic potential of PIK3CA-derived public neoantigens
Chris Klebanoff, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses novel T-cell receptor (TCR) gene therapy targeting public neoantigens. Public neoantigens derived from mutations in the PIK3CA oncogene were initially discovered via mass spectrometry-based immunopeptidomics screens and a candidate neoantigen compatible with HLA3 tissue was found to be immunogenic in a certain number of cancer types. A lead TCR clinical candidate that can bind to the neoantigen via a long CDR3β loop was additionally found. The specificity of the loop will reduce cross reactivity and pre-clinical studies have shown the cytotoxic potential of the TCR candidate. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
